HuidaGene Therapeutics Co., Ltd. is conducting a clinical trial for HG202, a CRISPR-Cas13 RNA-editing therapy aimed at treating neovascular age-related macular degeneration (nAMD). The market for nAMD therapies is significant, with anti-VEGF agents currently dominating but facing challenges such as decreased long-term efficacy and patient compliance issues due to frequent injections. HG202's potential for a one-time treatment could disrupt the existing market by offering a long-term solution for both responsive and non-responsive patients. The trial's success may position HuidaGene as a leader in innovative gene-editing therapies, particularly in ophthalmology, where unmet needs remain high. However, the competitive landscape includes established anti-VEGF therapies and emerging gene therapies, necessitating careful monitoring of clinical outcomes and market dynamics.